Jacobs Levy Equity Management
GALT icon

Jacobs Levy Equity Management’s Galectin Therapeutics GALT Stock Holding History

Jacobs Levy Equity Management’s Portfolio GALT Stock Details GALT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-139,714
Closed -$158K – 999
2016
Q3 		$158K Sell
139,714
-48,193
-26% -$85.7K ﹤0.01% 933
2016
Q2 		$276K Buy
+187,907
New +$276K 0.01% 905

Other funds holding GALT

DADC
D.A. Davidson & Co Great Falls, Montana $16.5B AUM 19.94% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AG
Advisor Group Phoenix, Arizona $14.5B AUM 24.86% 1-Year Est. Return
BCA
Benchmark Capital Advisors New York $101M AUM 0.8% 1-Year Est. Return
CCM
Courage Capital Management Nashville, Tennessee $70.6M AUM 13.29% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return
US Bancorp
US Bancorp Minneapolis, Minnesota $82.4B AUM 19.69% 1-Year Est. Return
VKH
Virtu KCG Holdings New York $3.6B AUM 17.11% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Jacobs Levy Equity Management's GALT Position: Q4 2016 in Review

Jacobs Levy Equity Management sold out of Galectin Therapeutics (GALT) in Q4 2016, closing a stake of 139,714 shares — an estimated $158K sold.

Jacobs Levy Equity Management first reported a position in GALT in Q2 2016 and held it in 2 quarters. The position peaked at $276K in Q2 2016. 43 funds tracked by Wall St. Rank hold GALT as of Q4 2016.

  • Jacobs Levy Equity Management reported no remaining Galectin Therapeutics position as of Q4 2016 after selling out during the quarter.
  • Jacobs Levy Equity Management sold 139,714 Galectin Therapeutics shares in Q4 2016, an estimated $158K.
  • Jacobs Levy Equity Management first reported a position in Galectin Therapeutics in Q2 2016 and held it in 2 quarters.
  • Jacobs Levy Equity Management's Galectin Therapeutics position peaked at $276K in Q2 2016.
  • 43 funds tracked by Wall St. Rank held Galectin Therapeutics as of Q4 2016.

Based on Jacobs Levy Equity Management's 13F filing for Q4 2016, filed 14 Feb 2017.